PR
PRLD.US Prelude Therapeutics Inc
- Market cap
- USD 265M
- P/E
- -
- P/B
- 2.20x
- ROE
- -39.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRLD.US undervalued?
Graham numberThe Graham number of Prelude Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prelude Therapeutics Inc fundamental analysis
No fundamental analysis for Prelude Therapeutics Inc yet.
Prelude Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody …
Full company profilePrelude Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Prelude Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00M | 12.1M | 21.2M |
| Gross Profit | -149K | -382K | -542K | -2.24M | -3.04M | -1.17M | 7.00M | 10.4M | - |
| Operating Income | -15.0M | -28.1M | -58.8M | -114M | -124M | -132M | -140M | -105M | -58.5M |
| EBITDA | -14.8M | -27.7M | -58.2M | -113M | -122M | -121M | -125M | -97.8M | -50.4M |
| Net Income | -14.7M | -27.6M | -56.9M | -111M | -107M | -122M | -127M | -99.5M | -49.1M |
| EPS | -9.31 | -0.85 | -1.30 | -2.33 | -2.27 | -2.02 | -1.68 | -1.29 | -0.48 |
| Balance Sheet | |||||||||
| Total Assets | 16.4M | 21.9M | 224M | 305M | 221M | 278M | 176M | 141M | 175M |
| Total Liabilities | 39.1M | 71.3M | 11.4M | 19.2M | 25.1M | 40.6M | 44.1M | 72.7M | 51.3M |
| Shareholders' Equity | -22.7M | -49.4M | 212M | 286M | 195M | 237M | 131M | 68.6M | 124M |
| Cash & Short-term Investments | 15.6M | 18.9M | 218M | 291M | 202M | 233M | 134M | 103M | 140M |
| Total Debt | - | 258K | - | 1.74M | 1.83M | 16.9M | 18.0M | 17.8M | 17.6M |
| Cash Flow | |||||||||
| Operating Cash Flow | -13.0M | -25.7M | -46.2M | -83.5M | -83.7M | -107M | -103M | -56.3M | -68.1M |
| Capital Expenditure | 529K | 780K | 621K | 2.32M | 3.02M | 3.51M | 764K | 67.0K | 46.7K |
| Free Cash Flow | -13.5M | -26.4M | -46.8M | -85.9M | -86.7M | -111M | -104M | -56.4M | -68.1M |
| Ratios | |||||||||
| ROE | - | - | -26.8% | -38.7% | -54.9% | -51.4% | -96.7% | -145.0% | -39.6% |
| ROA | -89.5% | -126.1% | -25.5% | -36.3% | -48.7% | -43.9% | -72.5% | -70.4% | -28.0% |
| Net Profit Margin | - | - | - | - | - | - | -1,816.8% | -819.6% | -231.3% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.07x | 0.14x | 0.26x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Prelude Therapeutics Inc dividends
Prelude Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Prelude Therapeutics Inc
- Insiders 13.76%
- Institutions 79.15%
- Public & others 7.09%
- Shares outstanding 65.1M
- Free float 22.1M
Top funds holding PRLD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.51M | 1.90% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 692K | 0.87% | 0.00% | Oct 2026 |
| Biotech Growth Ord | 347K | 0.43% | 0.00% | Jul 2026 |
| Fidelity Small Cap Index | 304K | 0.38% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 264K | 0.33% | -0.38% | Oct 2026 |
| PPF Helix Biotechnology I USD | 224K | 0.28% | +7.19% | Jul 2026 |
| Vanguard Russell 2000 ETF | 161K | 0.20% | +0.33% | Sep 2026 |
| Fidelity Extended Market Index | 137K | 0.17% | -28.61% | Sep 2026 |
| iShares Micro-Cap ETF | 84.5K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 72.9K | 0.09% | -0.05% | Sep 2026 |
| Schwab Small Cap Index | 67.6K | 0.08% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 59.4K | 0.07% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 51.9K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 49.5K | 0.06% | -19.41% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 37.0K | 0.05% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 36.9K | 0.05% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 Growth ETF | 30.1K | 0.04% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 29.6K | 0.04% | +0.91% | Oct 2026 |
Top institutions holding PRLD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 13.7M | 17.20% | +25.81% | Jun 2026 |
| Baker Bros Advisors LP | 10.1M | 12.69% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 6.48M | 8.11% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 3.38M | 4.23% | 0.00% | Jun 2026 |
| Kynam Capital Management, LP | 2.42M | 3.03% | +51.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.01M | 2.52% | +63.32% | Jun 2026 |
| BlackRock Inc | 1.80M | 2.25% | +458.43% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.02M | 1.28% | +82.65% | Jun 2026 |
| Two Sigma Investments LLC | 993K | 1.24% | +7.55% | Jun 2026 |
| ADAR1 Capital Management LLC | 901K | 1.13% | +489.50% | Jun 2026 |
| Millennium Management LLC | 845K | 1.06% | +120.78% | Jun 2026 |
| Acadian Asset Management LLC | 843K | 1.06% | +37.89% | Sep 2026 |
| Geode Capital Management, LLC | 842K | 1.05% | +178.34% | Jun 2026 |
| Adage Capital Partners Gp LLC | 766K | 0.96% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 504K | 0.63% | +56.40% | Jun 2026 |
| State Street Corp | 429K | 0.54% | +210.20% | Jun 2026 |
| UBS Group AG | 319K | 0.40% | +394.22% | Jun 2026 |
| Renaissance Technologies Corp | 298K | 0.37% | +5.87% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 285K | 0.36% | +81.02% | Jun 2026 |
| Northern Trust Corp | 241K | 0.30% | +380.05% | Jun 2026 |
Prelude Therapeutics Inc company profile
- Company name
- Prelude Therapeutics Inc
- Ticker
- PRLD.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 79
- Fiscal year end
- December
- Address
- 175 Innovation Boulevard, Wilmington, DE, United States, 19805
- Phone
- 302 467 1280
- Website
- preludetx.com
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Inc management
10- Dr. Krishna Vaddi D.V.M., Ph.D.Founder, CEO & Director · born 1966
- Mr. Bryant David Lim J.D.CFO, Chief Legal Officer & Corporate Secretary · born 1971
- Dr. Peggy A. Scherle Ph.D.Chief Scientific Officer · born 1962
- Ms. Aimee Crombie Ph.D.Senior VP and Head of Strategic Planning & Operations
- Dr. Madhu Pudipeddi Ph.D.Senior Vice President of Technical Operations
- Mr. Robert A. Doody Jr.Senior Vice President of Investor Relations
- Ms. Michele Porreca M.B.A.Chief People Officer
- Dr. Andrew P. Combs Ph.D.Executive VP & Chief Chemistry Officer · born 1967
- Mr. Naveen Babbar Ph.D.Senior Vice President of Translation Medicine
- Dr. Wan-Jen Hong M.D.Senior Vice President of Clinical Development · born 1979